CoChat
Sign Up
Cited by 113Angiogenesis and VEGF in CancerGlioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells

Machein, Kullmer, Rönicke, Machein, Krieg, Damert, Breier, Risau, Plate·1999·Neuropathology and Applied Neurobiology
DOI 10.1046/j.1365-2990.1999.00166.x
Open this paper in CoChat — free account

Abstract

Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is a mitogen and chemotactic factor for endothelial cells in vitro and an angiogenesis and vascular permeability factor in vivo. Due to its properties, VEGF is a candidate for both angiogenesis and vascular permeability/oedema induction which typically occur in glioblastomas. In this study we test the hypothesis that the antioedema effect of dexamethasone is mediated by downregulation of VEGF or VEGF receptor expression. VEGF mRNA and protein levels of two rat glioma cells lines, C6 and GS‐9L, were determined after incubation with dexamethasone under normoxic and hypoxic conditions. In normoxic C6 and GS9L cells, we observed 50–60% downregulation of VEGF mRNA by dexamethasone (P=0.015 and P=0.01, respectively). This effect was dependent on glucocorticoid‐receptor (GR) function. The inhibitory effect of dexamethasone on VEGF gene expression by tumour cells was markedly reduced by hypoxia which suggests that the upregulation of VEGF driven by hypoxia overcomes the effect of the dexamethasone. Dexamethasone did not alter VEGFR‐2 mRNA levels in human umbilical endothelial cells. In a subcutaneous glioma tumour model, we observed only a 15% decrease in VEGF mRNA expression in dexamethasone treated animals (n=12) compared with controls animals (P=0.24). We conclude that dexamethasone may decrease brain tumour‐associated oedema by reduction of VEGF expression in tumour cells. However, the highly reduced activity on hypoxic tumour cells suggests that dexamethasone efficacy may be limited by hypoxia in rapidly growing tumours.

Overview

Integrity signals

Registry

Crossref · 10.1046/j.1365-2990.1999.00166.x

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. Criscuolo GR, 1996, The genesis of peritumoural vasogenic brain oedemaand tumour cysts: a hypothetical role for tumour‐derived vascular permeability factor., Yale J Biol Med, 66, 277
  2. Galicich JH, 1961, Use of dexamethasone in treatment of cerebral oedema associated with brain tumours., J Lancet (Minneapolis), 81, 46
  3. Jakeman LB, 1993, Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis Endocrinol, 133, 848
  4. Kremer C, 1997, Upregulation of flk‐1/VEGF receptor‐2 by its ligand in a cerebral slice culture system., Cancer Res, 57, 3852

Cited by

Sorted by citations

See all 113

Related

See all

Metadata

Authors
Machein, Kullmer, Rönicke, Machein, Krieg, Damert, Breier, Risau, & Plate
Corresponding author
Plate
Venue
Neuropathology and Applied Neurobiology
Publisher
Wiley
Published
1999-04
Volume
25
Issue
2
Pages
104-112
ISSN
  • 0305-1846 (ISSN-L)
  • 1365-2990
DOI
10.1046/j.1365-2990.1999.00166.x
OpenAlex
W2133286797
Cited by
113
References
37
Citations by year
2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 6 · 2019: 5 · 2017: 2 · 2016: 5 · 2015: 3 · 2014: 4 · 2013: 2 · 2012: 4
FWCI
1.38
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 1009 d)
Locations
  • Neuropathology and Applied Neurobiology (publishedVersion)
  • PubMed (publishedVersion)
  • FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
vascular endothelial growth factor, dexamethasone, glioma, hypoxia, glucocorticoid receptor, VEGF receptor 2, angiogenesis, VEGF expression, C6 cells
MeSH terms
Animals, Cell Line, Dexamethasone, Endothelium, Vascular, Estradiol, Glioma, Glucocorticoids, Humans, Lymphokines, Progesterone, RNA, Messenger, Tumor Cells, Cultured, Umbilical Veins, Down-Regulation, Cell Hypoxia, Endothelial Growth Factors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review